Literature DB >> 22084369

Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study.

Laurence Lamant1, Keith McCarthy, Emanuele d'Amore, Wolfram Klapper, Atsuko Nakagawa, Maximo Fraga, Jadwiga Maldyk, Ingrid Simonitsch-Klupp, Ilske Oschlies, Georges Delsol, Audrey Mauguen, Laurence Brugières, Marie-Cécile Le Deley.   

Abstract

PURPOSE: The prognostic value of pathologic characteristics of childhood ALK-positive anaplastic large-cell lymphomas (ALCL), such as histologic subtypes, immunophenotype, and presence of the t(2;5) translocation or its variants, was assessed. PATIENTS AND METHODS: All 375 patients with systemic ALK-positive ALCL included in an international trial launched by the European Intergroup for Childhood Non-Hodgkin's Lymphoma were reviewed by an international panel of pathologists based on conventional hematoxylin and eosin-stained and immunostained sections and classified according to the 2001 WHO classification.
RESULTS: A small-cell (SC) or lymphohistiocytic (LH) component was observed in 114 (32%) of 361 patients, whereas ALCL of common type was diagnosed in 235 (65%) of 361 patients. Regarding the histologic subtyping of patients within the two categories of ALCL (with v without SC/LH component), the concordance between the national and international reviews was quite good, with a κ index equal to 0.67 (95% CI, 0.57 to 0.75). The presence of an SC/LH component was significantly associated with a high risk of failure (hazard ratio [HR], 2.0; 95% CI, 1.3 to 3.0; P = .002) in the multivariate analysis controlling for clinical characteristics, as well as the perivascular pattern (HR, 1.7; 95% CI, 1.1 to 2.7; P = .01), whereas CD3 positivity was significantly associated with a high risk of failure only in univariate analysis.
CONCLUSION: Our study, which to our knowledge includes the largest series of childhood systemic ALK-positive ALCL so far, demonstrates the adverse prognostic value of SC and/or LH morphologic features. Combining these histologic characteristics with other biologic or clinical factors might have a high potential for future risk stratification and treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22084369     DOI: 10.1200/JCO.2011.36.5411

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  36 in total

Review 1.  ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study.

Authors:  Ilske Oschlies; Jasmin Lisfeld; Laurence Lamant; Atsuko Nakazawa; Emanuele S G d'Amore; Ulrika Hansson; Konnie Hebeda; Ingrid Simonitsch-Klupp; Jadwiga Maldyk; Leonhard Müllauer; Marianne Tinguely; Markus Stücker; Marie-Cecile Ledeley; Reiner Siebert; Alfred Reiter; Laurence Brugières; Wolfram Klapper; Wilhelm Woessmann
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

2.  Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: a report from the children's oncology group.

Authors:  Sarah Alexander; Jacqueline M Kraveka; Sheila Weitzman; Eric Lowe; Lynette Smith; James C Lynch; Myron Chang; Marsha C Kinney; Sherrie L Perkins; Joseph Laver; Thomas G Gross; Howard Weinstein
Journal:  Pediatr Blood Cancer       Date:  2014-08-23       Impact factor: 3.167

Review 3.  [Malignant lymphomas in children and adolescents. Practical knowledge for diagnosis].

Authors:  I Oschlies; W Klapper
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

Review 4.  Pharmacotherapeutic Management of Pediatric Lymphoma.

Authors:  Christine Mauz-Körholz; Natascha Ströter; Julia Baumann; Ante Botzen; Katharina Körholz; Dieter Körholz
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

Review 5.  Adolescent and young adult lymphoma: collaborative efforts toward optimizing care and improving outcomes.

Authors:  Justine M Kahn; Nmazuo W Ozuah; Kieron Dunleavy; Tara O Henderson; Kara Kelly; Ann LaCasce
Journal:  Blood Adv       Date:  2017-10-10

6.  Leukemic presentation of ALK-positive anaplastic large cell lymphoma with a novel partner, poly(A) binding protein cytoplasmic 1 (PABPC1), responding to single-agent crizotinib.

Authors:  Dylan Graetz; Kristine R Crews; Elizabeth M Azzato; Ravi K Singh; Susana Raimondi; John Mason; Marcus Valentine; Charles G Mullighan; Ashley Holland; Hiroto Inaba; Vasiliki Leventaki
Journal:  Haematologica       Date:  2019-02-28       Impact factor: 9.941

7.  Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma.

Authors:  Yuka Iijima-Yamashita; Tetsuya Mori; Atsuko Nakazawa; Reiji Fukano; Tetsuya Takimoto; Masahito Tsurusawa; Ryoji Kobayashi; Keizo Horibe
Journal:  Int J Hematol       Date:  2017-10-13       Impact factor: 2.490

8.  Expression of CD8 is associated with non-common type morphology and outcome in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Authors:  Dmitriy Abramov; Ilske Oschlies; Martin Zimmermann; Dmitriy Konovalov; Christine Damm-Welk; Wilhelm Wössmann; Wolfram Klapper
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

9.  Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.

Authors:  Coralie Hoareau-Aveilla; Thibaud Valentin; Camille Daugrois; Cathy Quelen; Géraldine Mitou; Samuel Quentin; Jinsong Jia; Salvatore Spicuglia; Pierre Ferrier; Monica Ceccon; Sylvie Giuriato; Carlo Gambacorti-Passerini; Pierre Brousset; Laurence Lamant; Fabienne Meggetto
Journal:  J Clin Invest       Date:  2015-08-10       Impact factor: 14.808

Review 10.  Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead.

Authors:  Véronique Minard-Colin; Laurence Brugières; Alfred Reiter; Mitchell S Cairo; Thomas G Gross; Wilhelm Woessmann; Birgit Burkhardt; John T Sandlund; Denise Williams; Marta Pillon; Keizo Horibe; Anne Auperin; Marie-Cécile Le Deley; Martin Zimmerman; Sherrie L Perkins; Martine Raphael; Laurence Lamant; Wolfram Klapper; Lara Mussolin; Hélène A Poirel; Elizabeth Macintyre; Christine Damm-Welk; Angelo Rosolen; Catherine Patte
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.